Systemic lupus erythematosus debut with mild activity and its evolution
Abstract
Objectives: to assess whether patients with systemic lupus erythematosus (SLE) and low disease activity at the time of diagnosis have a more benign course of the disease vs those who have moderate/severe activity at the time of diagnosis.Materials and methods: observational, analytical, retrospective cohort study. Clinical records of patients diagnosed with SLE according to ACR 1982/1997 Criteria, SLICC 2012 or ACR/EULAR 2019, who attended the Rheumatology Section of Rivadavia hospital in CABA, Argentina, were reviewed.Results: a total of 100 patients diagnosed with SLE were included, of which 44% had mild activity, while the remaining 56% had moderate or severe activity at diagnosis. Statistically significant differences were observed between the group that had mild baseline activity vs the group that presented moderate/severe baseline activity, with the first group presenting fewer flares throughout the course of the disease (median of the first group 0 [IQR 0-1] vs median of the second, 1 [IQR 1-2]; p<0.01). Less organ involvement was observed throughout the course of the disease in those with mild baseline activity compared with moderate/severe baseline activity, with statistically significant differences in renal involvement (15.91% versus 55.36%; p<0.01).Conclusions: patients with low baseline activity had a more benign disease course, presenting fewer severe flares compared to patients who presented moderate to severe activity at disease onset.References
I. Ocampo-Piraquive V, Nieto-Aristizábal I, Cañas CA, Tobón GJ. Mortality in systemic lupus erythematosus: causes, predictors and interventions. Expert Review of Clinical Immunology 2018;14(12):1043-1053. doi:10.1080/1744666X.2018.1538789.
II. Lateef A, Petri M. Unmet medical needs in systemic lupus erythematosus. Arthritis Res Ther 2012;14 Suppl 4:S4.
III. Pego-Reigosa JM, Rua-Figueroa I, López-Longo FJ, Galindo-Izquierdo M, Calvo-Alen J, Olive-Marques A, et al; RELESSER Group, from the Spanish Society of Rheumatology Systemic Autoimmune Diseases Study Group (EASSER). Analysis of disease activity and response to treatment in a large Spanish cohort of patients with systemic lupus erythematosus. Lupus 2015;24:720-9.
IV. Edwards CJ, Lian TY, Badsha H, the CL, Arden N, Chng HH. Hospitalization of individuals with systemic lupus erythematosus. Characteristics and predictors of outcome. Lupus 2003;12:672-676.
V. Bandeira M, Buratti S, Bartoli M, et al. Relationship between damage accrual, disease flares and cumulative drug therapies in juvenile-onset systemic lupus erythematosus. Lupus 2006;15:515-520.
VI. Ugarte-Gil MF, Acevedo-Vásquez E, Alarcón GS, et al. The number of flares patients experience impacts on damage accrual in systemic lupus erythematosus. Data from a multiethnic Latin American cohort. Ann Rheum Dis 2015;74:1019-1023.
VII. Stoll T, Sutcliffe N, Mach J, Klaghofer R, Isenberg DA. Analysis of the relationship between disease activity and damage in patients with systemic lupus erythematosus. A 5-yr prospective study. Rheumatology (Oxford) 2004;43:1039-1044.
VIII. Narayanan S, Wilson K, Ogelsby A, Juneau P, Durden E. Economic burden of systemic lupus erythematosus flares and comorbidities in a commercially insured population in the United States. J Occup Environ Med 2013;55:1262-1270.
IX. Zhu TY, Tam LS, Lee VW, Lee KK, Li EK. The impact of flare on disease costs of patients with systemic lupus erythematosus. Arthritis Rheum 2009;61:1159-1167.
X. Zhu TY, Tam LS, Lee VW, Lee KK, Li EK. Relationship between flare and health-related quality of life in patients with systemic lupus erythematosus. J Rheumatol 2010; 37:568-573.
XI. Pollard C, Hartz S, Leage SL, Paget MA, Cook J, Enstone A. Elicitation of health state utilities associated with varying severities of flares in systemic lupus erythematosus. Health Qual Life Outcomes 2015;13:66.
XII. Steiman AJ, Urowitz MB, Ibanez D, Papneja A, Gladman DD. Prolonged clinical remission in patients with systemic lupus erythematosus. J Rheumatol 2014;41:1808-16.
XIII. Costedoat-Chalumeau N, Dunogué B, Morel N, Le Guern V, Guettrot-Imbert G. Hydroxychloroquine: a multifaceted treatment in lupus. Presse Med 2014;43:167-80.
XIV. Wallace DJ, Gudsoorkar VS, Weisman MH, Venuturu-palli SR. New insights into mechanisms of therapeutic effects of antimalarial agents in SLE. Nat Rev Rheumatol 2012;8(9):522-33.
XV. Olsen NJ, Schleich MA, Karp DR. Multifaceted effects of hydroxychloroquine in human disease. Semin Arthritis Rheum 2013;43:264-72.
XVI. Chambers SA, Allen E, Rahman A, Isenberg D. Damage and mortality in a group of British patients with systemic lupus erythematosus followed up for over 10 years. Rheumatology (Oxford) 2009;48:673-5.
XVII. Nossent J, Kiss E, Rozman B, Pokorny G, Vlachoyiannopoulos P, Olesinska M, et al. Disease activity and damage accrual during the early disease course in a multinational inception cohort of patients with systemic lupus erythematosus. Lupus 2010;19:949-56.
XVIII. Urowits MB, Gladman DD, Ibáñez D, Fortin PR, Bae SC, Gordon C, et al. Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort. Arthritis Care & Research 2012;64 (1):132-137. Doi: 10.1002/acr.20648.
XIX. Ugarte-Gil MF, Wojdyla D, Pons-Estel GJ, Quintana R, Gómez-Puerta JA, Catoggio LJ, et al. Predictors of remission and low disease activity state in systemic lupus erythematosus: data from a multiethnic, multinational latin american cohort. The Journal of Rheumatology 2019;46:10. doi:10.3899/jrheum.180433.
XX. Peschken CA, Wang Y, Abrahamowicz M, Pope J, Silverman E, Sayani A, Iczkovitz S, et al. Persistent disease activity remains a burden for patients with systemic lupus erythematosus. J Rheumatol 2019;46(2):166-175. doi: 10.3899/jrheum.171454.
XXI. Kalia S, Dutz JP. New concepts in antimalarial use and mode of action in dermatology. Dermatol Ther 2007;20:160-74.
XXII. Herman SM, Shin MH, Holbrook A, Rosenthal D. The role of antimalarials in the exacerbation of psoriasis: a systematic review. Am J Clin Dermatol 2006;7:249-57.
XXIII. Stelton CR, Connors DB, Walia SS, Walia HS. Hydro-chloroquine retinopathy: characteristic presentation with review of screening. Clin Rheumatol 2013;32:895-8.
XXIV. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA. Clinical efficacy and side effects of an-timalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 2010;69:20-8.
Copyright (c) 2022 Intellectual property rights: authors. Reproduction rights: Argentine Society of Rheumatology

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.